Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

Inclusion Criteria: * Newly diagnosed de novo AML who achieved complete remission (CR), including CRi and CRp after a maximum number of 2 cycles of induction chemotherapy. * Histologically or morphologically confirmed diagnosis of AML except for AML M3 (acute promyelocytic leukemia) * No contraindication to anthracyclines : decompensated or uncontrolled heart failure, recent myocardial infarction, current signs of cardiac impairment, uncontrolled arrhythmias, LVEF (left ventricular ejection fraction) \< 50% * Age ≥ 60 years and \< 75 years * ECOG performance status ≤2 * Written informed consent * No psychological, familial, social, or geographic reason that would compromise clinical follow up Exclusion Criteria: * Relapsed or refractory AML * Patients with acute promyelocytic leukemia (APL) * Patients with secondary type AML (post myelodysplastic syndrome MDS or therapy-related AML) * Severe pshyciatric or organic disorder, supposed to be independent from AML, that would contraindicate treatment * Subjects for which allogeneic HSCT is planned in CR1 * Known allergic or hypersensitivity to idarubicin or cytarabine or to any of the test compounds, materials * Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk * A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications